Mesoblast - MESO Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View MESO analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 1 year target prices for Mesoblast's shares. Their MESO share price forecasts range from $2.50 to $23.00. On average, they expect the company's stock price to reach $10.13 in the next twelve months. This suggests a possible upside of 221.4% from the stock's current price.
View analysts price targets for MESO or view top-rated stocks among Wall Street analysts.

Mesoblast's stock was trading at $2.91 at the beginning of 2023. Since then, MESO shares have increased by 8.2% and is now trading at $3.15.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 30th 2023.
View our MESO earnings forecast.

Mesoblast Limited (NASDAQ:MESO) announced its quarterly earnings data on Monday, February, 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.02. The company earned $2.13 million during the quarter, compared to analyst estimates of $1.50 million. Mesoblast had a negative net margin of 1,068.42% and a negative trailing twelve-month return on equity of 16.52%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

(MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Mesoblast's stock is owned by a number of institutional and retail investors. Top institutional shareholders include M&G Investment Management Ltd. (0.66%), Morgan Stanley (0.13%), Hennion & Walsh Asset Management Inc. (0.12%), Millennium Management LLC (0.08%), Group One Trading L.P. (0.00%) and Susquehanna International Group LLP (0.00%).

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MESO stock can currently be purchased for approximately $3.15.

Mesoblast (NASDAQ:MESO) has a market capitalization of $464.39 million and generates $7.66 million in revenue each year. The company earns $-91,350,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036, via email at schond.greenway@mesoblast.com, or via fax at 61-3-9639-6030.